Association of coagulation activation with clinical complications in sickle cell disease - Wikidata - awgldk - TriplyDB

Association of coagulation activation with clinical complications in sickle cell disease

Association of coagulation activation with clinical complications in sickle cell disease

http://www.wikidata.org/entity/Q34130633

about

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy.Vasculopathy and pulmonary hypertension in sickle cell disease.Elevated hypercoagulability markers in hemoglobin SC disease.Plasma levels of some coagulation parameters in steady state HBSC disease patients.Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.Increased yield of endothelial cells from peripheral blood for cell therapies and tissue engineering.Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice Contribution of Sickle Cell Disease to the Pediatric Stroke Burden Among Hospital Discharges of African-Americans-United States, 1997-2012.Decades after the cooperative study: a re-examination of systemic blood pressure in sickle cell disease.Pulmonary platelet thrombi and vascular pathology in acute chest syndrome in patients with sickle cell disease A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.Procoagulant microparticles in dogs with immune-mediated hemolytic anemia Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.Advances in understanding the pathogenesis of cerebrovascular vasculopathy in sickle cell anaemia.Interplay between coagulation and vascular inflammation in sickle cell disease.Low-molecular-weight heparins for managing vasoocclusive crises in people with sickle cell disease: a summary of a cochrane systematic review.Investigational selectin-targeted therapy of sickle cell disease.Defective nitric oxide metabolism in sickle cell disease.Prothrombotic aspects of sickle cell disease.Microparticles in sickle cell anaemia: promise and pitfalls.Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.Elevated D-dimer levels in African Americans with sickle cell trait Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobin.Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment.Coagulation profile of Sudanese children with homozygous sickle cell disease and the effect of treatment with omega-3 fatty acid on the coagulation parameters.Developing new pharmacotherapeutic approaches to treating sickle-cell disease.Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia.

P2860

Q24187057-0E91E05D-D8F1-4C2F-9A3D-B5A25DA9FC26 Q24201981-5DCA8B4C-522E-4C00-AC58-93A4DADB9810 Q28596621-DEED01CA-7583-4E8D-A5ED-6861961DAB66 Q33409969-257F8104-DA94-47A0-A30D-DA0022C441BE Q33574142-AD2C27BF-190F-4BF2-9498-2A55E636F799 Q33778831-6FC4193D-8A8A-45D1-8ECB-1B817E7B6122 Q33804615-D4C49C2A-C522-48DD-8FC3-EC9B74B1FC0F Q34466198-C37A2CD2-B430-4382-A54E-C979C9F6B43C Q35036717-848029F6-04E8-4790-A39D-FB325C6F7D24 Q35086394-4A9AE09D-A116-488E-844B-4FEBBCF14A9C Q35236050-F430BDC1-1487-49FB-8668-FFAA7DD7F744 Q35347392-6412E92D-0E3C-4A15-8C78-6AE3016E872C Q35754765-9B56EDE4-1EC7-4B88-988C-61DF79643A7E Q35810984-C3D3E9CB-C7CB-40BA-9421-39A39B574962 Q35881838-B1D1209C-D4F8-47AD-B069-D5D0C3E5922A Q36106316-FAB96253-E03C-442B-A278-EB45B58A952D Q36143261-4ACAF504-DD83-480A-82AF-1169224685C3 Q36218171-8CC0243E-3F6D-4107-9895-88A3FF06AEDF Q36275606-61F01C5A-0484-42A8-97C4-CD54A3D721BA Q36494197-43CA38E6-9F09-47C2-AB2D-ADF8B4066D5F Q36649213-36411CC0-4A39-4F4F-BA88-1FB6E3E0A748 Q36974952-37185D7E-8178-4A98-8AAF-395F58D4BEAB Q37033939-DBF00541-6124-4F93-B7A2-8C280255417D Q38089946-12F2737C-4D42-4230-A8EB-9214D55416F8 Q38099667-4070687F-DE55-4850-ADCB-EF86F703D331 Q38211660-FB5ECD82-90C6-4C08-82BD-F24AB4143E34 Q38253064-C36C14B0-8758-4383-BA8D-1B8B73A62AFB Q38267858-8895AF66-4FBC-4BF5-BDC3-11B998CEC087 Q38696998-2E9D3F04-4B39-4BE0-BAF0-6C316FE330DB Q38823104-942B4EDE-1ED1-4BF8-B183-0EDB2FF04215 Q39588275-7563EBAD-0D40-40F1-9E53-CD7E0EA8BF31 Q40526934-D74B2882-4556-4FBA-9134-FDDAE318D222 Q42821629-3D339D3B-0310-4646-9CBA-14BC6296DD51 Q43111402-206E3096-8676-40A7-B027-3667D23C7975 Q44040196-EE827632-8755-4230-A0F6-568A8191C6C3 Q47145599-B90D3D40-C939-4766-8200-36EA413D7558 Q50207951-5093F241-D6C9-49E9-910B-718380C4338C Q50230368-F1F46D33-F4CD-4C4F-ABF8-0F83857E9C5F Q54299957-5728AC3F-20C1-4EF4-9C3E-FF38B59ACE46

P2860

Association of coagulation activation with clinical complications in sickle cell disease

http://www.wikidata.org/entity/Q34130633

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Association of coagulation activation with clinical complications in sickle cell disease

@ast

Association of coagulation activation with clinical complications in sickle cell disease

@en

Association of coagulation activation with clinical complications in sickle cell disease

@nl

type

label

Association of coagulation activation with clinical complications in sickle cell disease

@ast

Association of coagulation activation with clinical complications in sickle cell disease

@en

Association of coagulation activation with clinical complications in sickle cell disease

@nl

prefLabel

Association of coagulation activation with clinical complications in sickle cell disease

@ast

Association of coagulation activation with clinical complications in sickle cell disease

@en

Association of coagulation activation with clinical complications in sickle cell disease

@nl

P1433

Q34130633-81BC439E-3936-4B81-8A3C-0BDE121D19DD

P1476

Q34130633-BCBADB31-BFB6-4015-84CD-4804941AD058

P2093

Q34130633-0E8776F3-1123-40AF-B4E9-36C9C8010070

Q34130633-240E1A7A-724C-4124-8124-AB89BE0E228D

Q34130633-3F42920E-898E-4DB9-94D3-CDA73FD2502E

Q34130633-3F5A0625-88C6-4C01-BF08-10C436A0E5EB

Q34130633-73AB976C-2DAB-44D0-95C1-8C95F270EF3F

Q34130633-74536FC7-0AC0-4AEF-8892-C0C2B9BD1FF3

Q34130633-8B525113-1C4F-4853-9043-849C9F58D16B

Q34130633-DA3D3604-44BA-4D76-AAC9-CCDF43E817C2

Q34130633-E3ACA73D-CC08-4F56-B6FD-CF9E9617491F

P2860

Q34130633-0D4B821D-51AA-4A93-BFE4-3A27DFB51B05

Q34130633-19BAD7EA-4A69-4C17-BDF5-7809C90B3ECA

Q34130633-1B581B50-6E78-4EF7-BFE9-E0198D113200

Q34130633-37575652-F438-4514-8B3E-00C0A8DC44EB

Q34130633-3D9257EB-126C-4DFE-AE67-E246930333C9

Q34130633-487F4B3D-93A8-44C1-B5BD-21AB9C7C20FA

Q34130633-4D354B88-6288-460A-AF89-68566801AA48

Q34130633-657CD3FE-0B83-43F9-BF27-CAA0B7E42CE5

Q34130633-6F764721-19D4-4FF7-9BCB-0C19D2CABBA4

Q34130633-758E8179-FD11-48A5-9907-55E2238AC5EC

P304

Q34130633-97FB2E08-CA59-4B3C-84CD-0DA09A6E64B9

P31

Q34130633-F23837DA-BD95-422F-B984-9C457B41DD74

P356

Q34130633-09C073CA-07A6-4D6E-B640-CDF52AB4B96B

P407

Q34130633-1A9D9A02-2967-4032-8651-FF8CEA4DAF4A

P433

Q34130633-B9A3276B-75EC-43E1-B361-AB32B524646D

P478

Q34130633-A5AD0520-2246-4B07-A46E-6BF04864682F

P577

Q34130633-CF7C5CBF-993D-41EB-8F73-2453531CA3FE

P5875

Q34130633-3C369CAB-819F-4041-B28E-F29E462F8B7F

P698

Q34130633-DE6EA3A3-B4FA-4CC5-BB1B-33C10DA305EB

P921

Q34130633-ECC3D22C-B4BA-43B4-B7D4-C8669297246B

P932

Q34130633-39C18DD3-8043-4E1E-8647-1715E11996C7

P356

JOURNAL.PONE.0029786

P1433

P1476

Association of coagulation activation with clinical complications in sickle cell disease

@en

P2093

Alan Hinderliter

http://www.w3.org/2001/XMLSchema#string

Dell Strayhorn

http://www.w3.org/2001/XMLSchema#string

John Delaney

http://www.w3.org/2001/XMLSchema#string

Julia E Brittain

http://www.w3.org/2001/XMLSchema#string

Kenneth I Ataga

http://www.w3.org/2001/XMLSchema#string

Nigel S Key

http://www.w3.org/2001/XMLSchema#string

Payal Desai

http://www.w3.org/2001/XMLSchema#string

Ryan May

http://www.w3.org/2001/XMLSchema#string

Susan Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Placenta growth factor in sickle cell disease: association with hemolysis and inflammation.

Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Endothelium: interface between coagulation and inflammation.

Sickle cell disease: the neurological complications.

Sickle cell anemia as an inflammatory disease

The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy.

Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin

Hypercoagulability in sickle cell disease: new approaches to an old problem.

Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.

P304

e29786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0029786

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221755678

http://www.w3.org/2001/XMLSchema#string

P698

22253781

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

3256184

http://www.w3.org/2001/XMLSchema#string